Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Burkitt Lymphoma 7Multiple Myeloma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Smoldering Multiple Myeloma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Down Syndrome 2Lung Neoplasms 1Leukemia, Plasma Cell 1Leukemia, Biphenotypic, Acute 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 29pembrolizumab 25Pemetrexed 25Specimen Handling 22Cisplatin 20Magnetic Resonance Spectroscopy 18Paclitaxel 15Gemcitabine 13Docetaxel 12durvalumab 9Nivolumab 8osimertinib 7Taxes 7Immunoglobulin G 7Disulfides 7130-nm albumin-bound paclitaxel 7atezolizumab 6Etoposide 6Platinum 5Cetuximab 51,2-diaminocyclohexaneplatinum II citrate 5X-Rays 4Ramucirumab 4Radiotherapy 4Radiation 4Observation 4Interviews as Topic 4Biopsy 4Albumin-Bound Paclitaxel 4patritumab deruxtecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × dexamethasone 21-phosphate × 30 days × Clear all
NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Active not recruiting
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡